National Center for Health Research https://validator.w3.org/feed/docs/rss2.html Why is the FDA approving questionable drugs? NCHR Written Public Comment to Advisory Council on Alzheimer’s Research, Care, and Services Regarding Plans for Updating the National Plan to Address Alzheimer’s Disease for 2026-2035. NCHR Written Public Comment to Advisory Council on Alzheimer’s Research, Care, and Services Should you get a blood test to predict future Alzheimer’s Disease? Should Mammograms Start at Age 30? Biennial Reports & Newsletters NCHR Written Comment on HHS National Plan To Address Alzheimer’s Disease Medical Devices Need User Fees to Improve Evidence Sunscreen 101: What You Need to Know When Health Insurance Companies Cheat Us Jobs, Fellowships, Internships & Volunteers Device firms back latest MDUFA deal, while patients want more postmarket safety Is artificial turf worth the risk? Can Belly Fat Cause Cancer and Other Serious Diseases? Public Comment of Generation Patient, National Center for Health Research, Patient Safety Action Network, and USA Patient Network in response to the Medical Device User Fees Amendments (MDUFA) VI Stakeholders Process and Commitment Letter Key Staff NCHR Public Comment on FDA Medical Device User Fee Amendments (MDUFA) VI for 2027-2032 FDA, In First Tobacco Action, Bans Flavors Expedited Investigational New Drug (IND) Pilot Program- Request for Information Testimony to FDA Tobacco Products Scientific Advisory Committee on Menthol Cigarettes Patient, Consumer, and Public Health Coalition Comments on Proposed Rule to Allow FDA to Regulate All Tobacco Products Breast implant removal is more popular than ever. Why? Are Medical Devices Proven to Work? NCHR Written Comment to OMB on the Proposed Regulation for Federal Financial Assistance Nonprofit Groups’ Letter to Secretary Price on the Tobacco “Deeming Rule” NCHR Comment on the USPSTF’s Draft Recommendations for Tobacco and Nicotine Use Prevention in Children and Adolescents: Primary Care Interventions Advancing Tobacco Control Practices To Prevent Initiation of Tobacco Use Among Youth and Young Adults, Eliminate Exposure to Secondhand Smoke, and Identify and Eliminate Tobacco- Related Disparities: Request for Information. Smoking Pipe Tobacco: Exposure and Health NCHR’s Comments on FDA’s Proposed Rule on Tobacco Product Applications NCHR Comments on FDA’s Notice on the Modified Risk Tobacco Product Application for Copenhagen Snuff Fine Cut Coalition Letter Urging Support for the Reversing the Youth Tobacco Epidemic Act NCHR’s Comments on FDA’s Notice on the Modified Risk Tobacco Product Applications for IQOS System With Marlboro Heatsticks NCHR’s Comments on USPSTF’s Draft Recommendation Statement for Tobacco Smoking Cessation in Adults, Including Pregnant Persons NCHR’s Comments on the Petition for Extension of Premarket Tobacco Product Application Filing Deadline from Keller and Heckman LLP NCHR’s Comments on Modified Risk Tobacco Product Application for Camel Snus NCHR Letter to Sen. Sanders in Support of the Childhood Diabetes Reduction Act NCHR Comments on Regulating Menthol in Tobacco Products FDA official bolting to Big Tobacco shines a light on the agency’s revolving-door problem NCHR Comments On FDA’s Requirements for Tobacco Product Manufacturing Practices Testimony of Dr. Diana Zuckerman at the Tobacco Products Scientific Advisory Committee Meeting on General Snus NCHR Public Comment on the Continued Implementation of the National Youth Tobacco Survey Testimony of Dr. Diana Zuckerman at the FDA Advisory Committee Meeting on Risks of 3 Heat Sticks And Other IQOS Tobacco Products NCHR Written Comment to FDA on Modified Risk Tobacco Product (MRTP) Applications for ZYN Nicotine Pouch Products NCHR Written Comment to FDA on the National Youth Tobacco Survey Testimony of Dr. Akashleena Mallick at the FDA TPSAC Meeting on ZYN Nicotine Pouch Products Submitted by Swedish Match U.S.A, Inc. Artificial Sweeteners: Do They Help You Lose Weight or Gain it? Are they Safe? NCHR’s Comments on USPSTF Draft Research Plan: Interventions for Tobacco Cessation in Adults, Including Pregnant Women NCHR Written Comment to FDA on the Commissioner’s National Priority Voucher (CNPV) Pilot Program NCHR Written Comment to FDA on the Plausible Mechanism Framework for Developing Individualized Therapies for Genetic Conditions The National Center for Health Research